Tailwind's Take: by publishing this index, investors in CYRX have a unique view into the growth of their industry. Expect this index to remain on the steep upslope for several years at a minimum.  IRVINE, Calif., Feb. 28, 2017 /PRNewswire/...
Tailwinds' Take: CYRX is in a sweet spot and will be for at least the next couple of years as they will continue to gain market share and revenue growth is set to go hyperbolic. The stock will likely...
Tailwinds' Take: this stock represents the definition of "tailwinds". They have a very large secular move happening underneath them and they are the only option when it comes to shipping these therapeutics, so are a direct beneficiary of all...
Tailwind's Take: this is a $2B market potentially and CYRX is the only pure play, fastest growing and best offering in the space. This could be a multi-year winner.  IRVINE, Calif., March 13, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW),...
Tailwinds' Take: CYRX holds a commanding position in the delivery of regenerative therapeutics. KITE's drug will be the second approved in this space. Expect more approvals and more Cryoport engagements going forward.  IRVINE, Calif., Sept. 5, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW)...
Tailwinds' Take: This transaction will provide the needed cash to see CYRX through to cash-flow positive, an event that will happen in either the last Q of this year or first of next. Once this transaction closes, I believe...
IRVINE, Calif., Oct. 26, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cold chain logistics company serving the life sciences industry, today announced the launch of a new website supporting its CryoStork(SM) cryogenic logistics solutions...
As of this morning, at $2.09 per share, we have added Cryoport (CYRX) to the Tailwinds Select Portfolio. Cryoport is in the business of shipping medicines. Any biologic that needs to be cryogenically suspended until it is dosed into a...
Tailwinds' Take: with recent approvals from Kite and Novartis, along with 20 Phase III drug partnerships, Cryoport is poised to have explosive revenue growth over the next few years. As they say, "Tip of the iceberg." IRVINE, Calif., Nov. 2, 2017 /PRNewswire/...
Tailwinds' Take: Moffitt is one of the leading cancer institutes in the US. Their selection of Cryoport is a major endorsement for the company as it looks to penetrate this growing market of biologics transportation. Expect more announcements like...